References
- JordanKKinitzIVoigtWBehlendorfTWolfHSchmollHSafety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day CTEur J Cancer20094571184118719135359
- NaeimADySLorenzKSanatiHWallingAAschSEvidence-based recommendations for cancer nausea and vomitingJ Clin Oncol200826233903391018688059
- WiserWBergerAPractical management of CT-induced nausea and vomitingOncology200519563764515945344
- MorranCSmithDAndersonDMcArdleCIncidence of nausea and vomiting with cytotoxic CT: a prospective randomised trial of antiemeticsBMJ1979161741323
- LohrLChemotherapy-induced nausea and vomitingCancer J2008142859318391612
- ZaidanMSoufiLHafeezMAbdelwahidMRasulKAssessing prescribing patterns for the prevention of CT-induced nausea and vomiting in the national center for cancer care and researchSaudi Pharm J201523438138727134539
- MitchellEGastrointestinal toxicity of chemotherapeutic agentsSemin Oncol200633110612016473649
- ChanATanSLowXYapKAntiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin CTNurs Res201261640541222960588
- LindleyCMHirschJDO’NeillCVTransauMCGilbertCSOsterhausJTQuality of life consequences of chemotherapy-induced emesisQual Life Res1992153313401299465
- GrallaRJOsobaDKrisMGRecommendations for the use of antiemetics: evidence-based, clinical practice guidelinesJ Clin Oncol19991792971299410561376
- RoilaFHerrstedtJAaproMGuideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnn Oncol201021suppl 5v232v24320555089
- BaschEPrestrudAAHeskethPJAmerican Society of Clinical OncologyAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201129314189419821947834
- CraverCGayleJBaluSBuchnerDPCN48 impact on hospital outpatient visit costs by initiating palonosetron versus other 5-hydroxytryptamine 3 receptor antagonists for prevention of chemotherapy induced nausea and vomiting (CINV) among patients with cancerValue Health2011143A163
- BallatoriERoilaFRuggeriBThe impact of chemotherapy-induced nausea and vomiting on health-related quality of lifeSupport Care Cancer200715217918516941136
- HeskethPJGrunbergSMGrallaRJThe oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study GroupJ Clin Oncol200321224112411914559886
- Poli-BigelliSRodrigues-PereiraJCaridesADAddition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomitingCancer200397123090309812784346
- GlausAKnippingCMorantRChemotherapy-induced nausea and vomiting in routine practice: a European perspectiveSupport Care Cancer2004121070871515278682
- HeskethPJChemotherapy-induced nausea and vomitingN Engl J Med2008358232482249418525044
- HeskethPJAaproMStreetJCCaridesADEvaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapySupport Care Cancer20101891171117719756774
- AaproMMolassiotisADicatoMThe effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)Ann Oncol20122381986199222396444
- de WitRHerrstedtJRapoportBThe oral NK 1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled Phase III clinical trialsEur J Cancer200440340341014746859